iBio CEO granted 479,000 stock options

iBio, Inc. reported that its Chief Executive Officer and Chief Scientific Officer, Martin Brenner, who also serves as a director, received a grant of stock options.

Rhea-AI Filing Summary

iBio, Inc. reported that its Chief Executive Officer and Chief Scientific Officer, Martin Brenner, who also serves as a director, received a grant of stock options. On January 28, 2026, he was awarded 479,000 stock options to purchase common stock at an exercise price of $2.23 per share.

According to the filing, 25% of the underlying shares will vest on the one-year anniversary of the grant date. The remaining 75% will vest in equal quarterly installments over the following 36 months, as long as Brenner remains employed by iBio. After this grant, he beneficially owns 479,000 stock options directly.

Insider Trade Summary

Grant/Award: 479,000 shares

Grant/Award 1 txn

Insider Brenner Martin

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	479,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 479,000 contracts (Direct)

Footnotes (1)

1. F1. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the iBio (IBIO) Form 4 filing report for Martin Brenner?

The filing reports a grant of stock options to Martin Brenner. On January 28, 2026, he received 479,000 stock options to buy iBio common stock at an exercise price of $2.23 per share, all held directly after the transaction.

How many stock options were granted to iBio (IBIO) CEO Martin Brenner?

Martin Brenner was granted 479,000 stock options. Each option gives him the right to purchase one share of iBio common stock at an exercise price of $2.23, with all 479,000 options shown as beneficially owned following the reported transaction.

What is the vesting schedule for Martin Brenner’s iBio (IBIO) stock options?

The options vest over several years. Twenty-five percent of the shares underlying the options vest on the one-year anniversary of the January 28, 2026 grant, and the remaining shares vest in equal quarterly installments over the next 36 months, contingent on continued employment.

What is the exercise price of the iBio (IBIO) stock options granted to Martin Brenner?

The options carry an exercise price of $2.23 per share. This means Brenner can buy iBio common stock at $2.23 for each of the 479,000 options, subject to the vesting schedule and the option term ending January 27, 2036.

When do Martin Brenner’s iBio (IBIO) stock options start and finish vesting?

Vesting starts one year after the January 28, 2026 grant date. At that time, 25% of the underlying shares vest, with the remaining shares vesting in equal quarterly installments over the following 36 months, assuming he remains employed by iBio throughout.

What role does Martin Brenner hold at iBio (IBIO) in this Form 4 filing?

Martin Brenner is identified as both a director and an officer of iBio. The remarks specify that he serves as Chief Executive Officer and Chief Scientific Officer, and the reported stock options are held directly in connection with his service to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 06:15 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brenner Martin

(Last) (First) (Middle)

C/O IBIO, INC.,

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$2.23	01/28/2026		A		479,000		01/28/2027	01/27/2036	Common Stock	479,000	$0	479,000	D

Explanation of Responses:

1. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Remarks:

Chief Executive Officer and Chief Scientific Officer

	/s/ Martin Brenner	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.